CSTL icon

Castle Biosciences

24.20 USD
+0.05
0.21%
At close Updated Oct 29, 9:35 AM EDT
1 day
0.21%
5 days
2.28%
1 month
8.23%
3 months
49.11%
6 months
21.91%
Year to date
-13.69%
1 year
-28.36%
5 years
-48.63%
10 years
13.08%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 798

0
Funds holding %
of 7,501 funds
0
Analysts bullish %
of 1 analysts
0
Positive news %
of 8 articles
Price charts implemented using Lightweight Charts™